{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Barrett ES"],"pubmed_abstract":["Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous endocrine-disrupting combustion by-products that have been linked to preterm birth. One possible mechanism is through disruption of placental corticotropin releasing hormone (pCRH), a key hormone implicated in parturition. As an extension of recent research identifying pCRH as a potential target of endocrine disruption, we examined maternal PAH exposure in relation to pCRH in a large, diverse sample. Participants, drawn from the CANDLE cohort, part of the ECHO-PATHWAYS Consortium, completed study visits at 16-29 weeks (V1) and 22-39 weeks (V2) gestation (n=812). Seven urinary mono-hydroxylated PAH metabolites (OH-PAHs) were measured at V1 and serum pCRH at V1 and V2. Associations between individual log-transformed OH-PAHs (as well as t"],"journal":["Frontiers in endocrinology"],"pagination":["1011689"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9691680"],"repository":["biostudies-literature"],"pubmed_title":["Prenatal polycyclic aromatic hydrocarbon (PAH) exposure in relation to placental corticotropin releasing hormone (pCRH) in the CANDLE pregnancy cohort."],"pmcid":["PMC9691680"],"pubmed_authors":["Robinson M","Loftus C","Kauderer S","Hazlehurst MF","Kannan K","Smith AK","Sathyanarayana S","Barrett ES","Workman T","Smith R","Zhao Q","LeWinn KZ","Bush NR"],"additional_accession":[]},"is_claimable":false,"name":"Prenatal polycyclic aromatic hydrocarbon (PAH) exposure in relation to placental corticotropin releasing hormone (pCRH) in the CANDLE pregnancy cohort.","description":"Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous endocrine-disrupting combustion by-products that have been linked to preterm birth. One possible mechanism is through disruption of placental corticotropin releasing hormone (pCRH), a key hormone implicated in parturition. As an extension of recent research identifying pCRH as a potential target of endocrine disruption, we examined maternal PAH exposure in relation to pCRH in a large, diverse sample. Participants, drawn from the CANDLE cohort, part of the ECHO-PATHWAYS Consortium, completed study visits at 16-29 weeks (V1) and 22-39 weeks (V2) gestation (n=812). Seven urinary mono-hydroxylated PAH metabolites (OH-PAHs) were measured at V1 and serum pCRH at V1 and V2. Associations between individual log-transformed OH-PAHs (as well as t","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-21T21:21:40.629Z","creation":"2025-04-05T18:23:41.198Z"},"accession":"S-EPMC9691680","cross_references":{"pubmed":["36440232"],"doi":["10.3389/fendo.2022.1011689"]}}